Why the Sirtex Medical Limited share price is climbing higher

The Sirtex Medical Limited (ASX:SRX) share price is expected to dive today following a downgrade this morning.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sirtex Medical Limited (ASX: SRX) share price could be volatile today, after the company announced major write-downs to its R&D assets and confirmed its guidance for the full year. Here's what you need to know:

  • Intangible clinical and R&D assets to the value of $90 million pre-tax will be written off, a non-cash impairment which will nevertheless impact statutory profits
  • Full year dose growth guidance expected to be around 5.5%
  • Constant-currency earnings before interest, tax, depreciation and amortisation (EBITDA) expected to be $72 million before one-off items
  • Staff headcount to be reduced 15% at a cost of $5.3 million

So What?

Due to the results of the SIRFLOX/FOXFIRE and SARAH/SIRveNIB studies not being successful, Sirtex's R&D impairment reflects the fact that funds invested in that research (which is counted as an 'asset' on the balance sheet) are now effectively worthless. This was already known, but is part of the new CEO's way of clearing the books and refocusing the company on his strategy.

Management is cutting R&D expenditure and clinical staff numbers to reduce costs and focus solely on the selling of SIR-Spheres, their primary product. The Chief Medical Officer, Dr David Cade, also seized his chance to depart after 14 years with the company.

Now What?

Fortunately, Sirtex has a strong balance sheet with minimal debt, and can weather the costs. However, today's update marks a step-change in the company's operations with it increasingly focused just on selling SIR-Spheres rather than also developing additional treatments.

This is a change from previously, where I felt that the company's R&D prospects made it a '10-year story' due to the time it takes for research to come to fruition.

Sirtex does appear to have plenty of room to grow, with just 12,000 dose sales per annum and an estimated market opportunity of 184,000 patients. However, many of these patients aren't reimbursed for SIR-Spheres and my view is that Sirtex's growth prospects are lower than might appear just from looking at these numbers. Sirtex also faces fierce competition from UK company BTG and its Theraspheres.

In my opinion today's news heightens the company's risks from a long-term perspective, although I am optimistic about the new CEO and continue to hold my shares.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »